Implementing ADA 2026 diabetes technology recommendations: opportunities and challenges for quality improvement in real-world care Authors: Khashayar Saybani, Ishani Ajantha Attanayake Mukaweti Sahabandu Mudiyanselage, Ainan Arshad Published: 2026 Key American Diabetes Association 2026 recommendations in diabetes technology The 2026 American Diabetes Association (ADA) Standards of Care position diabetes technologies as integral components of routine diabetes management rather than optional adjuncts, reflecting a shift towards broader eligibility, earlier initiation and sustained access across care settings.1 Across device categories, the guidance emphasises individualised, patient-centred selection, with technology choice informed by personal circumstances, preferences and capabilities and caregiver involvement where relevant.1 The standards uphold the complementary functions of many technologies. For people using continuous glucose monitoring (CGM), blood glucose monitoring is still crucial for safety and clinical decision-making, highlighting the necessity of context-appropriate use and dependable device accuracy.1 CGM is recommended from diagnosis and throughout the disease course for insulin-treated individuals and selected non-insulin therapies, with consistent use and uninterrupted access highlighted as critical for achieving maximal benefit.1 Automated insulin delivery (AID) systems are explicitly identified as the preferred method of insulin delivery across insulin-deficient diabetes, including type 1 diabetes and selected populations with type 2 diabetes, with consideration extended to individuals on basal insulin who are not meeting individualised glycaemic targets.1 Importantly, the ADA discourages the use of restrictive eligibility criteria—such as C-peptide levels, autoantibody status or duration of insulin use—when determining suitability for advanced technologies, reinforcing an access-oriented approach.1 The standards emphasise system-level responsibilities rather than efficacy. Standardised data reporting and shared access to device data are recommended to support clinical decision-making and quality improvement, while adequate education, continuous training and professional familiarity with developing devices are connected to safe and effective technology use.1 Education is framed as essential to optimising outcomes but should not function as a barrier to access.1 Overall, these recommendations reflect a more integrated and systems-focused approach to diabetes technology, balancing innovation with safety, continuity of access and individualised care. This framework provides a foundation for examining real-world implementation challenges and opportunities for quality improvement in technology-enabled diabetes care.1 Why the ADA 2026 technology updates matter now Diabetes management is increasingly shaped by technological innovation, particularly through the expanding use of CGM, AID systems and digital health tools. Evidence accumulated over the past decade shows that these technologies are associated with improved glycaemic control, fewer hypoglycaemic events and a reduced burden of self-management in a wide range of patient groups. However, uptake in routine clinical practice remains uneven, with persistent gaps in access and implementation. Against this backdrop, the 2026 ADA Standards of Care mark an important shift, strengthening and clarifying recommendations for the use of diabetes technologies. Evidence from meta-analyses demonstrates that CGM is associated with improved glycaemic control in adults with type 1 diabetes, with more advanced systems—including automated closed-loop technologies—providing incremental benefits that support wider, individualised use.2 These improvements are not limited to controlled trial settings: both randomised and real-world studies show enhanced glycaemic parameters with AID systems. Benefits are observed across paediatric and adult populations, with sustained increases in time-in-range over both short- and longer-term use.3 Collectively, these findings highlight the increasing clinical and practical significance of diabetes technologies and provide a rationale for the ADA’s expanded and clarified technology recommendations in 2026. By emphasising both demonstrated efficacy and applicability in real-world settings, the updated standards support broader integration of CGM and AID systems into routine care, while highlighting the need to address implementation challenges and quality improvement priorities to ensure equitable and effective adoption. Implementation challenges and quality gaps While the ADA provides clear and increasingly assertive recommendations for the use of diabetes technologies, translating these into routine clinical practice remains challenging. Evidence from real-world settings highlights a range of barriers that continue to limit effective implementation, particularly outside specialist care. Understanding these constraints is essential to inform quality improvement efforts and to ensure that advances in diabetes technology translate into meaningful and equitable improvements in patient care. Despite well-established clinical benefits, implementation of CGM in routine care remains constrained by multiple interrelated barriers. At a system level, quantitative evidence from primary care settings highlights limitations related to insurance coverage for patient costs, alongside time and staffing pressures, underscoring the need for improved clinician training and more supportive reimbursement frameworks.4 Beyond structural constraints, utilisation of diabetes technologies is also shaped by equity-related and psychosocial considerations, as well as user-related factors and device expectations, contributing to persistent variability in uptake and reinforcing the need for system-level approaches to enable equitable implementation.5 These inequities are reflected in measurable disparities in technology access and utilisation across patient populations. Evidence from paediatric diabetes populations highlights substantial disparities in both the initiation and sustained use of continuous glucose monitoring. Children from racial and ethnic minority groups, as well as those covered by public insurance, are less likely to initiate CGM in a timely manner, demonstrate lower overall utilisation, and are more likely to discontinue use compared with their White or privately insured counterparts.6 Disparities are also evident at the geographic level, with children residing in rural or underserved areas showing significantly lower engagement with CGM services than those in urban settings.7 These findings illustrate the influence of social determinants of health, differences in healthcare access and broader structural barriers on the uptake of diabetes technologies, reinforcing the importance of implementation strategies that explicitly address equity. In addition to these systemic factors, provider-level influences—including implicit bias and assumptions about patient capability or adherence—may also shape prescribing behaviours and contribute to unequal access to diabetes technologies.8 At the level of workforce capacity and clinical workflows, primary care clinicians frequently report limited experience, confidence, and integration of diabetes technologies into routine practice, reducing opportunities for timely therapeutic adjustment despite access to CGM data.9 Although consensus frameworks for interpreting CGM data exist—including recommendations for key metrics such as time-in-range, time-below-range and glycaemic variability—translation of these standards into routine clinical workflows remains inconsistent. This contributes to underutilisation of device-generated data and persistent treatment inertia, even in cases where glycaemic control remains suboptimal.1012 From a safety and reliability perspective, limited awareness of device accuracy constraints, including potential interference from medications and external factors, introduces avoidable risks, highlighting the importance of clinician education and system safeguards when integrating diabetes technologies into routine care.13 14 Taken together, these findings illustrate that gaps between guideline recommendations and real-world practice are driven not by a lack of evidence, but by system-related, workforce-related, safety-related and equity-related challenges that impede effective implementation. Addressing these barriers requires coordinated quality improvement approaches that move beyond device availability alone, focusing instead on service design, workforce development and equitable integration of technology into routine care. The following section considers the implications of these challenges for quality improvement and clinical practice. Implications for quality improvement and future directions Addressing the implementation challenges outlined above requires targeted quality improvement strategies across the workforce, policy and clinical workflows. Evidence from primary care indicates that clinician education is a critical enabler of effective continuous glucose monitoring implementation. In addition to web-based resources and structured training modules, conferences and professional meetings have been reported to support clinician knowledge development and confidence in the use of CGM technologies. The incorporation of CGM into everyday practice is further improved by multidisciplinary assistance, which includes input from clinical pharmacists, nursing staff and diabetes care and education specialists.15 16 Where such expertise is limited, alternative strategies include referral to virtual CGM initiation services or the use of structured online staff education programmes to build local capability.15 16 At a policy level, reimbursement arrangements need to adapt to reflect diabetes technology as a continuous component of care rather than a single, discrete intervention, to support sustained access.12 Incorporating the use of diabetes technologies within quality indicators and performance frameworks may also promote more consistent uptake and help to reduce unwarranted variation in clinical practice.17 Evidence indicates that the integration of digital support tools alongside structured training can help alleviate clinician workload and support more sustainable service redesign.18 Expert consensus within primary care further highlights the importance of workforce development and workflow support in managing the pressures associated with technology adoption.9 Implementation studies additionally demonstrate that early staff engagement, targeted education and the use of audit and feedback mechanisms can facilitate uptake while helping to mitigate staffing constraints.19 The methodical integration of diabetes technologies into standard clinical workflows should be prioritised in service redesign.20 To translate large volumes of device-generated data into meaningful clinical insights and reduce therapeutic inertia, this requires standardised procedures for data review, clearly defined escalation pathways and efficient integration of device data into electronic health records.21 Proactive identification of individuals most likely to benefit from technology-enabled interventions, using population-level analytical tools, may further support timely treatment intensification.22 Considerations of equity and safety must be explicitly embedded within implementation strategies, with expectations grounded in reality, as no diabetes technology currently available removes the need for ongoing self-care or active patient engagement. Without appropriate investment in education, structured onboarding and culturally sensitive support, wider use of technology may reinforce existing inequalities.2325 Clinicians therefore require a clear understanding of device limitations, potential sources of inaccuracy and the correct interpretation and use of CGM data—particularly as these technologies are increasingly utilised outside specialist services—to minimise avoidable harm.13 26 27 In order to support the efficient and equitable use of diabetes devices, these findings collectively highlight the necessity of coordinated quality improvement activities that incorporate workforce development, reimbursement mechanisms, data pipelines and safety considerations. To convert increased access into long-term gains in the standard of routine diabetic treatment, these system-level procedures must be strengthened. Future directions The rapid evolution of diabetes technologies, as highlighted in the 2026 ADA Standards of Care, presents both opportunities and challenges for quality improvement. Emerging CGM devices and advanced AID systems have the potential to enhance glycaemic outcomes and personalise care. However, keeping pace with these innovations can be difficult for clinicians and healthcare systems, requiring continuous professional development, adaptable workflows and infrastructure that supports safe implementation. Integrating new technologies within quality improvement frameworks will be essential to ensure equitable, effective and sustainable adoption. Conclusions The 2026 ADA Standards of Care emphasise that diabetes technologies are integral to routine management, offering opportunities to improve glycaemic outcomes and reduce treatment burden. However, evidence from real-world practice demonstrates persistent gaps in access, clinician training, workflow integration and safety oversight, which can limit the translation of these innovations into meaningful patient benefits. To close these gaps, coordinated quality improvement strategies—such as staff development, structured education, data standardisation and supporting reimbursement frameworks—are crucial. Healthcare systems may maximise the impact of future diabetes technologies and guarantee that improvements in care are both sustainable and patient-centred by incorporating fairness, safety and ongoing learning into implementation efforts.